ClinicalTrials.govpublic full text
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
lynch syndrome, recurrent endometrial carcinoma, recurrent endometrial clear cell adenocarcinoma, recurrent uterine corpus carcinosarcoma, mismatch repair deficiency, recurrent endometrial cancer
ClinicalTrials.gov
Show glossary
Search for terms
Hide glossary
Study record managers: refer to the
Data Element Definitions
if submitting registration or results information.
Record · ID 123442 · SHA-256 e5bfa50054351e7a
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.